Fibrinolysis in patients with diabetic nephropathy determined by plasmin-α2 plasmin inhibitor complexes in plasma

The Journal of diabetic complications Pub Date : 1990-10-01 DOI:10.1016/0891-6632(90)90018-Z

Mitsunori Yagame, Kazuhiko Eguchi, Daisuke Suzuki, Hideo Machimura, Hiroshi Takeda, Wataru Inoue, Kurumi Tanaka, Hideaki Kaneshige, Yasuo Nomoto, Hideto Sakai

{"title":"Fibrinolysis in patients with diabetic nephropathy determined by plasmin-α2 plasmin inhibitor complexes in plasma","authors":"Mitsunori Yagame, Kazuhiko Eguchi, Daisuke Suzuki, Hideo Machimura, Hiroshi Takeda, Wataru Inoue, Kurumi Tanaka, Hideaki Kaneshige, Yasuo Nomoto, Hideto Sakai","doi":"10.1016/0891-6632(90)90018-Z","DOIUrl":null,"url":null,"abstract":"<div>Activation of fibrinolysis in patients with diabetic nephropathy was determined by the plasma levels of plasmin-α2 plasmin inhibitor complexes (α2PIC) using a one-step sandwich enzyme immunoassay (EIA). Plasma levels of α2PIC in diabetic patients with persistent proteinuria were significantly higher than those in diabetic patients without proteinuria, patients with chronic glomerulonephritis, and healthy adults. Plasma levels of α2PIC in diabetic patients with intermittent proteinuria were also significantly higher than those of diabetic patients without proteinuria, patients with chronic glomerulonephritis, and healthy adults. Diabetic patients have been suggested to have a hypercoagulable state. The findings obtained from this study indicated that activation of fibrinolysis might counteract the hypercoagulable state in patients with diabetic nephropathy.</div>","PeriodicalId":77636,"journal":{"name":"The Journal of diabetic complications","volume":"4 4","pages":"Pages 175-178"},"PeriodicalIF":0.0000,"publicationDate":"1990-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0891-6632(90)90018-Z","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of diabetic complications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/089166329090018Z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 13

Abstract

Activation of fibrinolysis in patients with diabetic nephropathy was determined by the plasma levels of plasmin-α₂ plasmin inhibitor complexes (α₂PIC) using a one-step sandwich enzyme immunoassay (EIA). Plasma levels of α₂PIC in diabetic patients with persistent proteinuria were significantly higher than those in diabetic patients without proteinuria, patients with chronic glomerulonephritis, and healthy adults. Plasma levels of α₂PIC in diabetic patients with intermittent proteinuria were also significantly higher than those of diabetic patients without proteinuria, patients with chronic glomerulonephritis, and healthy adults. Diabetic patients have been suggested to have a hypercoagulable state. The findings obtained from this study indicated that activation of fibrinolysis might counteract the hypercoagulable state in patients with diabetic nephropathy.

查看原文本刊更多论文

血浆纤溶酶-α2纤溶酶抑制剂复合物对糖尿病肾病患者纤溶的影响

采用一步夹心酶免疫分析法(EIA)检测血浆纤溶酶-α2纤溶酶抑制剂复合物(α2PIC)水平，以确定糖尿病肾病患者纤溶酶的激活情况。伴有持续性蛋白尿的糖尿病患者血浆α2PIC水平明显高于无蛋白尿的糖尿病患者、慢性肾小球肾炎患者和健康成人。伴有间歇性蛋白尿的糖尿病患者血浆α2PIC水平也明显高于无蛋白尿的糖尿病患者、慢性肾小球肾炎患者和健康成人。糖尿病患者被认为具有高凝状态。本研究结果表明，纤溶的激活可能会抵消糖尿病肾病患者的高凝状态。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The Journal of diabetic complications

自引率

0.00%

发文量